公开(公告)号：US20200164084A1

公开(公告)日：2020-05-28

申请号：US16608608

申请日：2018-04-27

Applicant: NOVARTIS AG

Inventor： Alex Cortez ,  Bernhard Hubert Geierstanger ,  Rodrigo Andreas Hess ,  Timothy Z. Hoffman ,  Shailaja Kasibhatla ,  Tetsuo Uno ,  Xing Wang ,  Tom Yao-Hsiang Wu

IPC: A61K47/68 ,  A61K39/395 ,  A61K9/00 ,  A61P35/00 ,  A61K31/519 ,  A61K39/00

Abstract: Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies. In some embodiments, the conjugates are used in combination with a second therapeutic agent.

公开(公告)号：US10280139B2

公开(公告)日：2019-05-07

申请号：US15822930

申请日：2017-11-27

Applicant: NOVARTIS AG

Inventor： Bernhard Hubert Geierstanger ,  Jan Grunewald ,  Weijia Ou ,  Shifeng Pan ,  Tetsuo Uno ,  Yongqin Wan ,  Xing Wang

IPC: C07D207/09 ,  C07K5/02 ,  A61K47/68 ,  C07D401/12 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07K16/32

Abstract: Disclosed herein are novel compounds of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel compound linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

公开(公告)号：US11634497B2

公开(公告)日：2023-04-25

申请号：US16482173

申请日：2018-02-01

Applicant: NOVARTIS AG

Inventor： Steven Bender ,  Tracy Charlton ,  Anna Galkin ,  Bernhard Hubert Geierstanger ,  Scott Martin Glaser ,  Shailaja Kasibhatla ,  Mark Knuth ,  Sabine Rottmann ,  Sarah Rue ,  Glen Spraggon ,  Tetsuo Uno

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K39/00

Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

公开(公告)号：US10464969B2

公开(公告)日：2019-11-05

申请号：US16098289

申请日：2017-05-03

Applicant: NOVARTIS AG

Inventor： Matthew T. Burger ,  Yunho Jin ,  Tetsuo Uno

IPC: C07K7/64 ,  A61K47/68 ,  A61P35/00

Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates:

公开(公告)号：US20190144504A1

公开(公告)日：2019-05-16

申请号：US16098289

申请日：2017-05-03

Applicant: NOVARTIS AG

Inventor： Matthew T. Burger ,  Yunho Jin ,  Tetsuo Uno

IPC: C07K7/64 ,  A61P35/00 ,  A61K47/68

CPC classification number: C07K7/64 ,  A61K47/6831 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6863 ,  A61P35/00 ,  C07K16/32 ,  C07K2318/10

Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates:

公开(公告)号：US12171839B2

公开(公告)日：2024-12-24

申请号：US17833077

申请日：2022-06-06

Applicant: Novartis AG

Inventor： Anthony Edward Boitano ,  Matthew Burger ,  Susan E. Cellitti ,  Michael P. Cooke ,  Catrin Finner ,  Bernhard Hubert Geierstanger ,  Yunho Jin ,  Si Tuen Lee-Hoeflich ,  HongNgoc Thi Pham ,  Siew Ho Schleyer ,  Kathrin Tissot ,  Tetsuo Uno ,  Ben Wen

IPC: C07K16/00 ,  A61K38/07 ,  A61K38/12 ,  A61K47/68 ,  C07K16/28 ,  C07K16/46

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

公开(公告)号：US11596695B2

公开(公告)日：2023-03-07

申请号：US16701576

申请日：2019-12-03

Applicant: Novartis AG

Inventor： Bernhard Hubert Geierstanger ,  Weijia Ou ,  Tetsuo Uno

IPC: A61K47/68 ,  C07K16/32 ,  C07K16/28

Abstract: The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.

公开(公告)号：US10392421B2

公开(公告)日：2019-08-27

申请号：US15961531

申请日：2018-04-24

Applicant: NOVARTIS AG

Inventor： Bernhard Hubert Geierstanger ,  Jan Grunewald ,  Yunho Jin ,  Weijia Ou ,  Tetsuo Uno ,  Yongqin Wan ,  Xing Wang

IPC: C07K5/02 ,  A61K47/68 ,  C07K7/02 ,  C07K16/32

Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

公开(公告)号：US09938323B2

公开(公告)日：2018-04-10

申请号：US15524197

申请日：2015-11-05

Applicant: NOVARTIS AG

Inventor： Jan Grunewald ,  Yunho Jin ,  Weijia Ou ,  Tetsuo Uno

IPC: A61K38/00 ,  C07K7/64 ,  C07K16/22 ,  C07K16/30

CPC classification number: C07K7/64 ,  C07K16/22 ,  C07K16/30 ,  C07K2319/30

Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates:

公开(公告)号：US12180291B2

公开(公告)日：2024-12-31

申请号：US18164519

申请日：2023-02-03

Applicant: Novartis AG

Inventor： Steven Bender ,  Tracy Charlton ,  Anna Galkin ,  Bernhard Hubert Geierstanger ,  Scott Martin Glaser ,  Shailaja Kasibhatla ,  Mark Knuth ,  Sabine Rottmann ,  Sarah Rue ,  Glen Spraggon ,  Tetsuo Uno

IPC: C07K16/28 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00

Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.